Radiopharm Theranostics (ASX: RAD) — Company Overview, News & Financial Data
Radiopharm Theranostics develops and commercializes radiopharmaceutical products for cancer treatment.
Radiopharm Theranostics
Radiopharm Theranostics is a clinical-stage biotechnology company focused on the development of radiopharmaceutical therapies and diagnostics for novel oncology targets. The company develops a portfolio of targeting platforms, including nanobodies, monoclonal antibodies, peptides, and small molecules, to deliver diagnostic and therapeutic radioisotopes directly to cancer cells. Its key pipeline candidates address significant unmet medical needs in conditions such as brain metastases, solid tumors expressing PD-L1, and other aggressive cancers. Headquartered in Australia, the company collaborates with nuclear medicine suppliers and research institutions to advance its radiopharmaceutical programs through clinical development.
Snapshot
Operations
Products and/or services of Radiopharm Theranostics
- Brain Metastases Imaging Diagnostics: Radiopharmaceutical imaging candidate utilizing fluorine-18 pivalate designed for positron emission tomography imaging to detect and evaluate brain metastases in patients with solid tumor malignancies across phase 2 clinical trials.
- PD-L1 Targeted Nanobody Therapeutics: Radiotherapeutic candidate utilizing engineered nanobodies targeting programmed death-ligand 1 expressing solid tumors, designed to selectively deliver ionizing radiation to tumor cells while sparing healthy tissue in clinical evaluation.
- Solid Tumor Monoclonal Antibodies: Monoclonal antibody-based radiopharmaceutical therapy candidate designed to target specific cell surface receptors on solid tumors, undergoing phase 1/2 clinical studies to assess safety and therapeutic response.
- Nanobody Radiopharmaceuticals: Engineered single-domain antibody targeting platforms that bind with high affinity to tumor antigens, enabling precise delivery of diagnostic isotopes and therapeutic radioisotopes for oncology indications.
- Peptide and Small Molecule Ligands: Synthetic peptide and small-molecule targeting agents designed for rapid clearable delivery of diagnostic and therapeutic radionuclides to targeted receptor sites across various solid tumor types.
- Academic Research Joint Venture: Strategic collaborative enterprise with an academic oncology research center dedicated to co-developing novel target discovery programs and clinical radiopharmaceutical therapeutics for unaddressed cancer indications.
Radiopharm Theranostics executive team
- Paul Edward-Alexander HopperFounder & Executive Chairman
- Riccardo CanevariMD, CEO & Director
- Dimitris VoliotisChief Medical Officer
- Aaron LauritaChief Financial Officer
- Hitesh GoelHead of Project Management
- Nathan JongJoint Company Secretary
- Amritha SushilJoint Company Secretary
Latest news about Radiopharm Theranostics
Radiopharm Theranostics raises $12.5M in placement
AustraliaRadiopharm Theranostics reports 93% trial success
AustraliaRadiopharm Theranostics reports positive Phase 1 trial results
AustraliaRadiopharm completes enrolment for brain metastases trial
AustraliaRadiopharm advances to Cohort 3 in cancer trial
AustraliaRadiopharm commences Phase 1 advanced prostate cancer trial
Australia
Recent announcements
What Radiopharm Theranostics (RAD) has told the market, newest first.
- Non-Compliance with Listing Rule 10.11
- RAD Completes Meeting with US FDA for Development of RAD101
- Notification of cessation of securities - RAD
- Change of Director's Interest Notice (RC)
- Appendix 4G and Corporate Governance Statement
- Annual Report and Form 20-F
Key financials
Reported results for Radiopharm Theranostics, in AUD.
- Market cap
- 18.8M
- Revenue (TTM)
- 12.9M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.0
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 2.8M | -68.3M | -55.1M | |
| 13.4M | -38.2M | -36.7M | |
| 299.2K | -47.2M | -47.9M | |
| 292.4K | -40.3M | -34.6M |